Abstract:Introduction: The escalating global surge in Rifampicin-resistant strains poses a formidable challenge to the worldwide campaign against tuberculosis (TB), particularly in developing countries. The frequent reports of suboptimal treatment outcomes, complications, and the absence of definitive treatment guidelines for Rifampicin-resistant spinal TB (DSTB) contribute significantly to the obstacles in its effective management. Consequently, there is an urgent need for innovative and efficacious drugs to address Rifampicin-resistant spinal tuberculosis, minimizing the duration of therapy sessions. This study aims to investigate potential targets for DSTB through comprehensive proteomic and pharmaco-transcriptomic analyses. Methods: Mass spectrometry-based proteomics analysis was employed to validate potential DSTB-related targets. PPI analysis confirmed by Immunohistochemistry (IHC) and Western blot analysis. Results: The proteomics analysis revealed 373 differentially expressed proteins (DEPs), with 137 upregulated and 236 downregulated proteins. Subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses delved into the DSTB-related pathways associated with these DEPs. In the context of network pharmacology analysis, five key targets—human leukocyte antigen A chain (HLAA), human leukocyte antigen C chain (HLA-C), HLA Class II Histocompatibility Antigen, DRB1 Beta Chain (HLA-DRB1), metalloproteinase 9 (MMP9), and Phospholipase C-like 1 (PLCL1)—were identified as pivotal players in pathways such as "Antigen processing and presentation" and "Phagosome," which are crucially enriched in DSTB. Moreover, pharmaco-transcriptomic analysis can confirm that 58 drug compounds can regulate the expression of the key targets. Discussion: This research confirms the presence of protein alterations during the Rifampicin-resistant process in DSTB patients, offering novel insights into the molecular mechanisms underpinning DSTB. The findings suggest a promising avenue for the development of targeted drugs to enhance the management of Rifampicin-resistant spinal tuberculosis.

Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice

Studies on Rifampicin and Isoniazid-induced Hepatotoxicity Using in Vitro Primary Hepatocytes

Exploration of the underlying mechanisms of isoniazid/rifampicin‐induced liver injury in mice using an integrated proteomics and metabolomics approach

Screening of Biomarkers and Toxicity Mechanisms of Rifampicin-Induced Liver Injury Based on Targeted Bile Acid Metabolomics

Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs

Integration of metabolomics and proteomics analysis to explore the mechanism of neurotoxicity induced by receipt of isoniazid and rifampicin in mice

Rifampicin-induced ER stress and excessive cytoplasmic vacuolization instigate hepatotoxicity via alternate programmed cell death paraptosis in vitro and in vivo

The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.

First-line Anti-Tuberculosis Drugs Induce Hepatotoxicity: A Novel Mechanism Based on a Urinary Metabolomics Platform.

Rifampicin Exacerbates Isoniazid-Induced Toxicity in Human but Not in Rat Hepatocytes in Tissue-Like Cultures

Integrative Network Analysis of Rifampinregulated Mirnas and Their Functions in Human Hepatocytes

Effects and Mechanisms of Rifampin on Hepatotoxicity of Acetaminophen in Mice

Research on characteristics of liver injury induced by rifampicin in mice

Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes

Proteomics Analysis of Isoniazid Toxicity in Rat Liver

Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: A review

Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis

Correlation study about the genetic ploymorphisms of OATP1B1 and clinical hepatotoxicity induced by rifampicin

Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model

The Multistate Tuberculosis Pharmacometric Model: a Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model for Studying Drug Effects in an Acute Tuberculosis Mouse Model

Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy